Fazendo a diferença na vida das
pessoas há mais de 100 anos
Buscar
Tamanho da fonte

Joining forces to build our new future

At Teva, we continually evaluate and pursue growth opportunities that advance our goal of being a stronger, more diversified organization with the scale and resources to drive value across our business today and in the future.

The acquisition delivers on these objectives, while enabling us to take a leading position in our transforming industry.

This strategic acquisition brings together two leading generics businesses with complementary strengths, brands and cultures, providing patients with more affordable access to quality medicines, and creating significant financial benefits for Teva stockholders.

Our newly combined company offers the richest product pipeline in the generic industry and will continue to lead the way with complementary technologies and product portfolios, offering more differentiated and durable products than any other generic company of this scale.

Read more in the press release.

Últimas notícias


Estudo demonstra potencial de fremanezumabe para atender as necessidades de pacientes com enxaqueca crônica e episódica
Estreva - Notificação de Desabastecimento
Comunicado de Descontinuação do Produto Clopidogrel
Brasil tem nova opção de tratamento para esclerose
Comunicado - Suspensão temporária de importação do Colpotrofine®
Comunicado de Recolhimento Voluntário e Preventivo - Trisenox (trióxido de arsênio)
FDA aprova o medicamento AUSTEDO™ (deutetrabenazina) da Teva para o tratamento da Doença de Huntington
No ritmo da tecnologia - Aplicativo de música auxilia na marcha de pacientes com
Descontinuação de Importação de Produtos
Teva Launches Liquid Formulation of TREANDA®
Teva Announces COPAXONE® Recognized as "Brand of the Year"
TEVA TO ACQUIRE LABRYS BIOLOGICS
Teva Completes Acquisition of Labrys